EMPFIELD JAMES R. 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 8, 2022
Insider Transaction Report
Form 4
EMPFIELD JAMES R.
SVP, Drug Discovery
Transactions
- Exercise/Conversion
Common Shares
2022-03-04$8.40/sh+25,000$210,000→ 35,000 total - Sale
Common Shares
2022-03-04$30.79/sh−18,315$563,919→ 10,000 total - Tax Payment
Common Shares
2022-03-07$30.23/sh−695$21,010→ 11,805 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-04−25,000→ 0 totalExercise: $8.40Exp: 2027-03-12→ Common Shares (25,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-07−2,500→ 0 totalExercise: $8.40Exp: 2027-03-12→ Common Shares (2,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-07−40,000→ 0 totalExercise: $6.76Exp: 2026-02-07→ Common Shares (40,000 underlying) - Exercise/Conversion
Common Shares
2022-03-07$8.40/sh+2,500$21,000→ 12,500 total - Tax Payment
Common Shares
2022-03-04$31.42/sh−6,685$210,043→ 28,315 total - Exercise/Conversion
Common Shares
2022-03-07$6.76/sh+40,000$270,400→ 51,805 total - Tax Payment
Common Shares
2022-03-07$30.23/sh−8,952$270,619→ 42,853 total - Sale
Common Shares
2022-03-07$30.54/sh−31,048$948,206→ 10,000 total - Sale
Common Shares
2022-03-07$30.62/sh−1,805$55,269→ 41,048 total
Footnotes (6)
- [F1]Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- [F4]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.5161 to $30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- [F6]Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.